A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025

Hu Y, Ou SHI

Lung Cancer: Targets and Therapy 2025, 16:147-159

Published Date: 31 October 2025